Intellia's gene editing therapy shows early potential in rare heart condition
Intellia Therapeutics' early clinical data on gene editing treatment for ATTR-CM show potential benefits in improving heart function. NTLA-2001 demonstrated positive results, reducing the problematic protein and modifying the progression of the disease. This promising therapy is now being evaluated in a Phase III trial.